Novadip: Novadip's bone graft material unifies fractures in 100% of patients
Novadip's bone graft material NVDX3 has seen all patients achieve bone fracture union in a 12-month Phase Ib/IIa proof-of-concept study. The post Novadip's bone graft material unifies fractures in 100% of patients appeared first on Clinical Trials Arena.
Read full article »
Novadip is a Belgium-based biopharmaceutical company that researches and commercializes tissue regeneration therapies for the treatment of cancer and orthopedic conditions.
Read more